{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:30:25Z","timestamp":1792301425884,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":2993,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.7861\/clinmedicine.16-1-55","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T06:19:47Z","timestamp":1454307587000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Advances in pathogenesis and treatment of systemic sclerosis"],"prefix":"10.1016","volume":"16","author":[{"given":"Christopher P","family":"Denton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.16-1-55_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcp174","article-title":"Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study","volume":"103","author":"Nihtyanova","year":"2010","journal-title":"QJM"},{"key":"10.7861\/clinmedicine.16-1-55_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00439-011-1137-z","article-title":"Unraveling the genetic component of systemic sclerosis","volume":"131","author":"Mart\u00edn","year":"2012","journal-title":"Hum Genet"},{"key":"10.7861\/clinmedicine.16-1-55_bib4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa067655","article-title":"A polymorphism in the CTGF promoter region associated with systemic sclerosis","volume":"357","author":"Fonseca","year":"2007","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.16-1-55_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar4230","article-title":"Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells","volume":"15","author":"Gilbane","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.7861\/clinmedicine.16-1-55_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.7861\/clinmedicine.16-1-55_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.38928","article-title":"Review: cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib8","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib9","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1002\/art.38078","article-title":"Endothelial injury in a transforming growth factor \u03b2-dependent mouse model of scleroderma induces pulmonary arterial hypertension","volume":"65","author":"Derrett-Smith","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.16-1-55_bib10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/annrheumdis-2011-200940","article-title":"Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis","volume":"71","author":"Maurer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.16-1-55_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1164\/rccm.201408-1464OC","article-title":"Impaired BMPRII signalling in a TGF\u03b2 dependent mouse model of pulmonary hypertension and in systemic sclerosis","volume":"191","author":"Gilbane","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.7861\/clinmedicine.16-1-55_bib12","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.16-1-55_bib13","first-page":"581","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.16-1-55_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.16-1-55_bib16","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.7861\/clinmedicine.16-1-55_bib17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/BOR.0b013e3282e6f534","article-title":"Adult stem cell treatment of scleroderma","volume":"19","author":"Tyndall","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3899\/jrheum.090668","article-title":"Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis","volume":"37","author":"Herrick","year":"2010","journal-title":"J Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib19","unstructured":"19 European Scleroderma Observational Study. Available online at: www.ssc-esos.net [Accessed 28 October 2015].,"},{"key":"10.7861\/clinmedicine.16-1-55_bib20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.16-1-55_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK Systemic Sclerosis Study Group: Digital vasculopathy in systemic sclerosis","author":"Hughes","year":"2015","journal-title":"Rheumatology"},{"key":"10.7861\/clinmedicine.16-1-55_bib22","first-page":"2655","article-title":"Scleroderma Lung Study Research Group","volume":"354","author":"Tashkin","year":"2006","journal-title":"Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med"},{"key":"10.7861\/clinmedicine.16-1-55_bib23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.7861\/clinmedicine.16-1-55_bib24","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"25 Suppl","key":"10.7861\/clinmedicine.16-1-55_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.16-1-55_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ahj.2015.04.003","article-title":"Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis","volume":"170","author":"Zhang","year":"2015","journal-title":"Am Heart J"},{"issue":"25 Suppl","key":"10.7861\/clinmedicine.16-1-55_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Gali\u00e8","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.16-1-55_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.7861\/clinmedicine.16-1-55_bib29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"10.7861\/clinmedicine.16-1-55_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s40674-014-0004-1","article-title":"Management of renal involvement in scleroderma","author":"Stern","year":"2015","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib31","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/rheumatology\/keq147","article-title":"Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre","volume":"49","author":"Thoua","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"6 Suppl 86","key":"10.7861\/clinmedicine.16-1-55_bib32","first-page":"82","article-title":"Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms","volume":"32","author":"Tauber","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 86","key":"10.7861\/clinmedicine.16-1-55_bib33","first-page":"214","article-title":"Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis","volume":"32","author":"Hansi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.7861\/clinmedicine.16-1-55_bib34","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/1756-0500-7-594","article-title":"Impaired quality of life in patients with systemic sclerosis compared to the general population and chronic dermatoses","volume":"7","author":"Bretterklieber","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.7861\/clinmedicine.16-1-55_bib35","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.16-1-55_bib36","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1002\/art.30432","article-title":"Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations","volume":"63","author":"Meune","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.16-1-55_bib37","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/art.38381","article-title":"Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis","volume":"66","author":"Domsic","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824027428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824027428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.16-1-55","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:38:15Z","timestamp":1761460695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824027428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1470211824027428"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.16-1-55","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in pathogenesis and treatment of systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.16-1-55","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2016. All rights reserved.","name":"copyright","label":"Copyright"}]}}